Quality of Life (QOL)

Patients receiving REACTINE® reported significantly greater improvement in QOL—and significant reductions in impairment at work—vs placebo^*†‡

A study used the 28-question version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), a validated, allergy-specific measurement of overall QOL which measures 7 domains:

Activities
Sleep
Nasal symptoms
Eye symptoms
Non-nose, Non-eye symptoms
Practical problems
Emotional

In seasonal allergic rhinitis, REACTINE® significantly improved adult patients’ QOL vs placebo

Demonstrated improvement in quality of life in adults with SAR measured by the RQLQ at week 1 and week 2

_{Change in baseline scores = 3.3 and 3.2 for REACTINE® and placebo, respectively. §P < 0.001.}

_{Adapted from Murray,}_{et al}_.

Demonstrated improvement in individual RQLQ domains at week 2

_{॥P < 0.001 vs placebo. ¶MID (minimally important difference). A change of ≥0.5 from baseline in RQLQ score defined as the smallest difference perceived by patients as being beneficial or clinically meaningful. A change of ≥1.0 and ≥1.5 from baseline represent a moderate and large change, respectively.}

_{Adapted from Murray,}_{et al}_.

REACTINE® reduced work impairment in adults with seasonal allergic rhinitis*‡

This study assessed the impact of allergy treatment on self-reported activity impairment using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire, which measures performance based on^‡:

Impairment at work/school (i.e., work hours missed, impairment at work, overall-work impairment, classroom hours missed, impairment in classroom, overall classroom impairment)
Activity impairment (i.e., limitations on regular daily activities such as shopping and child care)

Work productivity and activity impairment-allergy specific (WPAI-AS) domain score change at Week 2 *‡

_{WPAI-AS=Work Productivity and Activity Impairment-Allergy Specific}

_{**F-test p < 0.001 vs placebo.}

_{Adapted from Murray, et al.}

Footnotes

*Randomized, placebo-controlled, 3-week study of adult patients with seasonal allergic rhinitis (n=431 for each treatment group).  

^†Patient disease-specific quality of life was assessed using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), which measures 7 domains: activities, sleep, nasal symptoms, eye symptoms, non-nose, non-eye symptoms, practical problems, and emotional.

^‡Impact on self-reported activity impairment was assessed using the Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire, which measures performance based on impairment at work/school (i.e., work hours missed, impairment at work, overall-work impairment, classroom hours missed, impairment in classroom, overall classroom impairment) and activity impairment (i.e., limitations on regular daily activities such as shopping and child care)

References